Table 1.
Baseline characteristics of the study populations
| Whole study population (n=2607) | Enriched comorbidities subgroup (n=342)* | ||
|---|---|---|---|
| Sex | |||
| Male | 724 (27·8%) | 72 (21·1%) | |
| Female | 1883 (72·2%) | 270 (78·9%) | |
| Age at vaccination (years) | 47·7 (12·5) | 49·3 (13·4) | |
| Range | 18·1–84·9 | 19·5–83·3 | |
| Age group (years) | |||
| <46 | 1204 (46·1%) | 152 (44·4%) | |
| 46–65·99 | 1202 (46·2%) | 141 (41·2%) | |
| ≥66 | 201 (7·7%) | 49 (14·3%) | |
| BMI (kg/m2) | 25·6 (4·8) | 25·1 (4·8) | |
| Range | 11·0–63·5 | 11·0–42·5 | |
| BMI group (kg/m2)† | |||
| <25 | 1343/2577 (52·1%) | 190/338 (56·2%) | |
| 25–29·99 | 816/2577 (31·7%) | 98/338 (29·0%) | |
| ≥30 | 417/2577 (16·2%) | 50/338 (14·8%) | |
| Comorbidities | |||
| Hypertension | 301 (11·55%) | 46 (13·45%) | |
| Dyslipidemia | 184 (7·06%) | 30 (8·77%) | |
| Autoimmune disease | 160 (6·14%) | 39 (11·40%) | |
| Diabetes | 139 (5·33%) | 25 (7·31%) | |
| Heart disease | 79 (3·03%) | 15 (4·39%) | |
| Lung disease | 79 (3·03%) | 18 (5·26%) | |
| Coagulation disorder | 46 (1·76%) | 9 (2·63%) | |
| Immunosuppression‡ | 32 (1·23%) | 12 (3·51%) | |
| Allergic disease§ | 20 (0·77%) | 6 (1·75%) | |
| Liver disease | 18 (0·69%) | 4 (1·17%) | |
| Kidney disease | 16 (0·61%) | 3 (0·88%) | |
| Pregnancy | 8 (0·31%) | 2 (0·58%) | |
Data are n (%), mean (SD), or n/N (%) unless otherwise indicated. BMI=body-mass index.
*
Subgroup with enriched co-morbidities was established comprising health-care workers who underwent at least two neutralisation assays during the 5 weeks of follow-up.
†
Denominator shows the number of participants for whom BMI was available.
‡
Included organ transplantation; being on biologic therapy, chemotherapy, or steroids; and splenectomy.
§
Defined as at least one event of anaphylaxis that required immediate treatment.